Innovative Medicine Backed by the Power of
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug development.
Neuroscience
BXCL501 is an investigational, proprietary, orally dissolving,
thin film formulation of dexmedetomidine designed for the
treatment of agitation and opioid withdrawal symptoms.
Immuno-Oncology
BXCL701 is an investigational, orally-administered, systemic
innate immunity activator in development for the treatment of
aggressive forms of prostate cancer and advanced solid tumors
that are refractory or treatment naïve to
checkpoint inhibitors.
Jan 19, 2022
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial OfficerVIEW RELEASE
Jan 04, 2022
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceVIEW RELEASE
Dec 15, 2021
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s DiseaseVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jan 21, 2022 04:00 PM
MARKET/SYMBOL
BTAI
PRICE
16.68
CHANGE
-0.75 (-4.3%)
